 Connection
Daniel Sherbenou to Cell Proliferation
This is a "connection" page, showing publications Daniel Sherbenou has written about Cell Proliferation.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.216 |
|
|
|
-
Sherbenou DW, Su Y, Behrens CR, Aftab BT, Perez de Acha O, Murnane M, Bearrows SC, Hann BC, Wolf JL, Martin TG, Liu B. Potent Activity of an Anti-ICAM1 Antibody-Drug Conjugate against Multiple Myeloma. Clin Cancer Res. 2020 11 15; 26(22):6028-6038.
Score: 0.112
-
Sherbenou DW, Hantschel O, Turaga L, Kaupe I, Willis S, Bumm T, Press RD, Superti-Furga G, Druker BJ, Deininger MW. Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia. Leukemia. 2008 Jun; 22(6):1184-90.
Score: 0.047
-
Forsberg PA, Hammes A, Abbott D, Sherbenou DW, Rossi A, Jayabalan D, Niesvizky R, Mark TM, Ely S. Cellular proliferation by multiplex immunohistochemistry identifies aggressive disease behavior in relapsed multiple myeloma. Leuk Lymphoma. 2019 08; 60(8):2085-2087.
Score: 0.025
-
Lee NK, Zhang Y, Su Y, Bidlingmaier S, Sherbenou DW, Ha KD, Liu B. Cell-type specific potent Wnt signaling blockade by bispecific antibody. Sci Rep. 2018 01 15; 8(1):766.
Score: 0.023
-
O'Hare T, Walters DK, Stoffregen EP, Sherbenou DW, Heinrich MC, Deininger MW, Druker BJ. Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib. Clin Cancer Res. 2005 Oct 01; 11(19 Pt 1):6987-93.
Score: 0.010
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|